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ABSTRACT
Background: M. leprae was presumed as an aetiologic agent in DLL, without specific microbiologic stu-
dios in the past. The sequencing of the genome through genetic testing led to the discovery of a new
species M. lepromatosis by Han et al. in 2008.
Materials and methods: The genetic analysis of the phylogeny of bacteria, based on the analysis of the
16S rRNA coding regions and other genes (eg, rpoB, rpoT, hsp65, mmaA, fibF-rpsO) appears to be helpful in species
discrimination. Twenty genes and pseudogenes (22,818 bp of sequence) proved that in the phylogenetic tree
M. leprae and M. lepromatosis are closely related. On the other hand, the differences were great, which gave rise to
the distinction between the two species. Detected insertions in both species of mycobacteria in the rRNA and
mmaA genes were similar to each other and were found only in the human genome, which confirms the close
relationship during M. leprae and M. lepromatosis evolution of genomes in the human species.
Results: The first population-based study analysing the presence of both mycobacteria indicates that
M. lepromatosis came to America with human populations migrating from Asia through the Strait of Bering,
in contrast to M. leprae, which came to America with the colonists and as a result of the slave trade.
Conclusions: The latest experiments with M. lepromatosis showed that it is a specific agent in DLL, not
only in the endemic area in Mexico, but also in different parts of the world. M. lepromatosis was also found
in other forms of multibacillary leprosy, or as a dual infection with M. leprae, as well. There are great
expectations that genetic methods with the sequencing of the whole genome will lead to a better under-
standing of some of the mysteries behind leprosy.
(Int Marit Health 2012; 63, 4: 213–218)
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THE SITUATION OF LEPROSY TODAY
Leprosy is a chronic, systemic, and infectious disease
caused by Mycobacterium leprae, affecting principally the
peripheral nerves and the skin. Complications due to neur-
opathy can result in deformity and disability with remaining
stigmatisation.
The highest prevalence of leprosy cases worldwide is
present in the developing countries, mainly in South–East
Asia (India), Latin America (Brazil, Mexico), and Central
Africa.
The introduction of effective multidrug therapy by the
WHO in the year 1982 decreased the number of cases from
14 million to about 250,000 in recent years [1–3].
There is a dilemma: the number of new cases detected
yearly is persistently high with active leprosy, often with
grade-2 disabilities. The disparity between prevalence and

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new case detection over the years emphasises the lasting
epidemiological threat of leprosy [4]. The chain of transmis-
sion has not been broken [5–7].
INTRODUCTION
The epidemiological agent of leprosy is M. leprae,
an obligate intracellular pathogen, discovered by
G. Hansen in 1873, and genome sequenced by S.T. Cole
in 2001 [8].
M. leprae differs from other human bacilli by non-cul-
tivation in vitro, extremely slow generation time (14 days),
and long incubation period (2–14 years). M. leprae has
a unique ability to infect peripheral nerves with the inva-
sion of Schwann cells and vascular endothelial cells [9–
–12]. Transmission of the disease is not conclusively prov-
en, although it is probably person-to-person via nasal
droplet infection or by long contact with infected persons
[6, 13]. The role of environmental reservoirs is not com-
pletely resolved.
Shepard in 1960 [14] demonstrated the multiplica-
tion of M. leprae by inoculation into footpads of mice and
later into the nude (nu/nu) mouse. This material has been
used as a culture medium for different investigations to
identify the organism of M. leprae, genetic characterisa-
tions, and others. The experimental model of animal lep-
rosy was demonstrated by Kirchheimer and Storrs in 1971
[15]. Nine-banded armadillos inoculated with M. leprae
develop fully disseminated infection with the involvement
of internal organs and nerves and characteristic histo-
pathological picture of leprosy [9].
Armadillos, living in some parts of the Southern Unit-
ed States, are a large reservoir for M. leprae. Leprosy pa-
tients residing in these areas have the possibility of expo-
sure to armadillo-born M. leprae. The latest investigations
revealed that the infective strains of M. leprae are identi-
cal both in animals and patients. There is a supposition
that leprosy may be a zoonosis in this part of the US [16].
Leprosy presents great diversity in clinical and histo-
pathological manifestations due to immunological and
genetic response. Classification identifies on the one
hand tuberculoid leprosy (TT) with a high degree of cell-
mediated immunity and solitary skin lesions often with
undetectable bacilli (paucibacillary leprosy) (Fig. 1). On
the other hand, lepromatous leprosy (LL) presents numer-
ous nodular lesions, containing a large number of bacilli
(multibacillary leprosy) with a characteristic anergy to
M. leprae and low degree of cell-mediated immunity
[17–19] (Fig. 2).
Leprosy reactions are the most dangerous events in
the course of the disease among 30–50% of patients.
They represent acute inflammatory and immunological
complications, leading to severe nerve impairment and
disability. Type I reaction occurs in paucibacillary leprosy
with exacerbation of existing lesions without constitution-
al symptoms. The cardinal features of type II reaction are
deep, painful nodules, often ulcerating. Erythema no-
dosum leprosum (ENL) is a systemic disease with high fe-
ver, malaise, and involvement of any organ or tissue where
the bacilli are found. (neuritis, irydocyclitis, orchitis, and
others) (Figs. 3, 4) [9, 20, 21].
Figure 1. The tuberculoid lesion (TT) in paucibacillary leprosy,
well defined with distinctly elevated border
Figure 2. Multibacillary lepromatous leprosy (LL) in a 12-year-
-old boy. Numerous disseminated nodules with typical infiltration
of ear lobes
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DIFFUSE LEPROMATOUS LEPROSY (DLL).
LUCIO’S PHENOMENON/ERYTHEMA
NECROTISANS
Concerning the history and nomenclature, the disease
was reported by Lucio and Alvadoro in 1852, and later by
Latapi and Chévez-Zamora in 1948. DLL is also called Dif-
fuse Leprosy of Lucio and Latapi or Lucio’s phenomenon/
/erythema necrotisans. The Caribbean DLL is a severe and
rare form of leprosy with high mortality, common in Mexico.
Occasional cases were reported worldwide, including Asia,
Africa, North America, and Brazil. The clinical pictures of
DLL appear as diffuse, shiny infiltrations of the skin with no
reactional phase in the initial stage. Gradually spreading
erythema (purple in colour) is a signal of haemorrhagic inf-
arcts. Plagues and blister formations, and later painful ne-
crotic ulcers are healing with atrophic, stellar scars. This
form of reaction is called Lucio’s phenomenon/erythema
necrotisans (Fig. 5). Clinically, there are additional symptoms
occurring in multibacillary leprosy such as: dysaesthenia,
anhidrosis, madarosis, alopecia, and destructive rhinitis. His-
tological findings suggest that Lucio’s phenomenon is a vas-
cular disorder produced by massive, direct invasion of vascu-
lar endothelial cells by M. leprae. Dilatation of vessels, en-
dothelial proliferation, luminal occlusion, thrombosis, and
ischaemic necrosis are the cardinal features [22–26].
Vasculonecrosis reactions are present in Lucio’s phe-
nomenon and in ENL. Despite the possibility of distinguish-
ing them through clinical and histopathological characteris-
tics, both are often used as synonyms. This may have
therapeutic implications, justifying the use of different drugs
in these two kinds of reaction. For instance: Thalidomide
gives excellent results in ENL but is worthless in Lucio’s phe-
nomenon [27].
Erythema necrotisans, being confined to multibacillary
lepromatous leprosy, needs not only clinical and histopatho-
logical endorsement for the diagnosis but also genetic and
molecular investigations. The next step for better under-
standing of the unclear pathogenesis of Lucio’s phenome-
non is the discovery of a new species of M. leprae — Myco-




In 2001, owing to M. leprae whole genome sequencing
and comparing it with the genomes of other mycobacteria,
it was discovered that the genome of the leprosy mycobacte-
Figure 3. Erythema nodosum leprosum (ENL) in multibacillary
leprosy with large nodules placed deeply
Figure 4. Erythema nodosum leprosum (ENL) in acute stage with
blister formation and ulceration, clinical picture resembles early
stage of Lucio’s phenomenon
Figure 5. Typical skin lesions of diffuse lepromatous leprosy
caused by Mycobacterium lepromatosis (by courtesy of Xiang Yang
Han MD and permission from Int J Dermatol)
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rium had significantly reduced. This reduction was the re-
sult of massive loss of large parts of the genome, leaving
only a gene essential for the transmission, infectivity, and
survival in human cells. A key role in this process was
played by repetitive sequences (RLEP, REPLEP, LEPREP,
and LEPRPT). This suggests targeted mycobacterial spe-
ciation [8, 29].
Compared to other mycobacterial species, the Mycobac-
terium leprae genome is small. For example, the genome of
leprosy consists of 3.2 Mbps (Mbps – million base pairs) as
compared to the genome of Mycobacterium tuberculosis,
the volume of which amounts to 4.4 Mbps [30].
Leprosy as a disease of man has been known since an-
cient times [31]. Lucio’s phenomenon, an aggressive form
of leprosy, was described in 1852. Only thanks to genetic
testing made in 2008, was it discovered that is caused by
a separate species [28].
Genetic analysis of the phylogeny of bacteria is based
on the analysis of conservative (almost invariant) regions
(DNA sequences) of the bacterial genome [32]. They are
usually the 16S rRNA coding regions and other genes (e.g.
rpoB-RNA polymerase b subunit, rpoT-RNA polymerase
d factor, hsp65-65kDa heat shock protein, mmaA-metyl my-
colic acid synthases 3 and 4, and fibF-rpsO-ryboflavin ki-
nase and ribosomal protein S15). Using this methodical
approach, it is possible to detect the presence of bacterial
species whose genome sequence is not yet sequenced [28].
The difference between M. leprae and M. lepromatosis
in the studied regions was 2.1% and was the basis for the
distinction of a new species. Testing the rRNA segment tak-
en from the sample from a DLL patient had 1,504 bp and,
comparing to the corresponding section in the M. leprae,
showed 97.9% identity. As a result of the careful analysis of
rRNA sequences 19 nucleotide insertion was detected. This
insertion was present in a place that in the genome of lep-
rosy is occupied by 16 nucleotide insertion, which is highly
characteristic of this species. The two insertion sequences
were not similar to each other, which is also proved by the
distinction between M. leprae and M. lepromatosis. It is in-
teresting that very similar sequences were found in the hu-
man genome, which may indicate a long history of common
evolution of mycobacterial and the human species [33].
Gene sequences of mmaA and riff-rpsO from an analysed
case of the M. lepromatosis showed a great difference in
comparison to the sequence of M. leprae, which were 14%
and 8.5%, respectively. In addition, the analysis of mmaA
gene sequences from both mycobacteria revealed a 21 nu-
cleotide sequence similar to the rRNA insertion described
above, which was found only in the human genome, con-
firming the close relationship during Mycobacterium genome
evolution in the human species. Compared to other myco-
bacteria (including M. avium, M. tuberculosis), the differ-
ences in the genes mmaA and riff-rpsO were even higher
(19–27%). It should be noted that in the rpoT gene a three-
times-repeated CGAGCCAATACAGCA sequence unique to
M. lepromatosis was detected [33]. In the future, if the pres-
ence of the repeated sequence is confirmed using a larger
group of cases, this sequence repetition could be a specific
marker for M. lepromatosis. However, hsp65 and rpoB genes
as compared to the sequences of other mycobacteria
showed differences in the sequence of about 7%. The dif-
ferences described above give rise to a diagnosis of a new
species of mycobacteria [28].
Thanks to further research analysing sequences of
20 genes and pseudogenes (22,818 bp) it was found that
in the phylogenetic tree M. leprae and M. lepromatosis are
closely related. However, the difference between the two
species gives rise to their distinction. G+C content of the
sequences in the both mycobacteria was almost identical
and amounted to 58.6% (M. lepromatosis) and 58.8%
(M. leprae), respectively. The similarity between the sequences
tested in these mycobacteria was 93% on average for the
coding sequence and 79.1% in the case of sequences of
pseudogenes. The overall sequence similarity was only
90.9%, which provides a basis to distinguish the two spe-
cies such as M. leprae and M. lepromatosis. In order to in-
vestigate phylogenetic relationships between both mycobac-
terials, synonymous (dS) and non-synonymous (dN) muta-
tions in protein-coding sequences were used. Studies have
shown that they have evolved from a common ancestor
about 10 million years ago, after the massive reduction in
its genome, as evidenced by the strong resemblance of the
evolutionarily neutral pseudogenes between the two spe-
cies of mycobacteria. Through the genetic analysis of
M. leprae and M. tuberculosis it was found that the evolution
of the ancestor of M. leprae and M. lepromatosis diverged
about 66 million years ago with M. tuberculosis [34].
The above research and analysis show that both spe-
cies evolved from a common ancestor, the massive genome
reduction of which occurred before the separation of the
two species of mycobacteria. In addition, the evolution of
mycobacteria was carried out in close contact with an in-
fected human species more than 100,000 years ago.
It should be noted that the above-described research
made it possible to distinguish the two species of mycobac-
teria and enabled the analysis of epidemiological and clini-
cal correlation [35]. In the future, this may help in the treat-
ment and control of the spread of these mycobacterial in-
fections. Despite the success in identifying and
distinguishing between the two species of mycobacteria, the
described populations of patients showing clinical signs of
infection of M. leprae and M. lepromatosis PCR tests were
negative in some cases. This is probably due to degrada-
tion of DNA in random samples [33].
www.intmarhealth.pl 217
Maria Kowalska, Artur Kowalik, Mycobacterium leprae: pathogenic agent in leprosy
The leprosy genome is very stable because it shows very
little variation between the isolates from different parts of the
world [31]. Single nucleotide polymorphisms (SNP) occur with
a frequency of 1/48,000 base pairs in the genome of M. lep-
rae. However, in the M. tuberculosis genome SNP is already
found at a frequency of 1/300 bp. These results point to
a genome stability and make it extremely useful for tracking the
migration of human populations over tens of thousands of years,
so called phylogeographic analysis. These studies have recently
challenged the widely held view that leprosy was taken to Ame-
rica with human populations migrating through the Bering Strait.
Genetic studies have shown that leprosy came to North Amer-
ica with European colonists. However, leprosy mycobacterium
reached South America as a result of the slave trade from the
African continent [31, 34]. Until recently, it was suspected that
leprosy in Europe was introduced by Greek soldiers from the
army of Alexander the Great while returning from the Indian
campaign. Population genetic studies of patients with leprosy
showed the dissemination of M. leprae from Africa through
the Middle East to Europe [31]. In contrast to M. leprae migra-
tion, the first population-based study analysing the presence
of both mycobacteria in Mexico indicates that M. lepromatosis
came to America with human populations migrating from Asia
through the Bering Strait [34, 36].
M. LEPROMATOSIS: THE LATEST
CLINICO–PATHOLOGIC INVESTIGATIONS
Han et al. [36] differentiated the leprosy agents among
120 patients with various forms of the disease in Mexico,
2012. The aetiological species was confirmed in 87 patients,
33 were PCR-negative. The investigators tested DNA extract-
ed from archived skin biopsies, using PCRs that targeted
the unique 16SrRNA genes and others.
M. lepromatosis was found in 63.2% of patients, M. lep-
rae in 20.7%, and dual infection in 16.1% of cases. The re-
sult verified that M. lepromatosis was the specific cause of
all DLL patients and was also found in other forms of multi-
bacillary leprosy (LL), but not in paucibacillary leprosy (TT).
The coexistence of M. leprae and M. lepromatosis probably
develops in endemic countries like Mexico.
The clinical picture in patients infected with M. lepro-
matosis showed a diffused cutaneous infiltrate with no nod-
ules and evident skin anaesthesia, whereas those infected
with M. leprae presented macules, numerous nodules, and
plagues. Patients with dual infection showed features of both
groups. The younger age predominated in M. lepromatosis
infected cases [36].
Ongoing studies confirm that new species M. leproma-
tosis exists beyond Mexico and was identified in Singapore
(endemic area) causing DLL in two patients, with dual, fatal
infection. M. lepromatosis gene sequences from Singapore
patients matched 99.9% with a known Mexican strain, and
they matched the corresponding M. leprae sequences
89.2% [37]. Another report comes from Canada presenting
leprosy-like illness associated with M. lepromatosis [38].
New cases will be reported soon from Burma and Brazil [per-
sonal communication with X.Y. Han].
CONCLUSIONS
Leprosy remains a major global health problem and is
not going to disappear. The infection is curable, but not pre-
ventable. The reported new active cases registered each year
remain the same, or are even increasing in endemic coun-
tries. Progress has been made concerning the immunology
and immunopathology of leprosy, but still should be focused
on genomic and molecular identification. The discovery of
M. lepromatosis by X. Y. Han in DLL and other forms of leprosy
have important implications for the disease spectrum and its
clinical picture. Further epidemiological and clinical evidence
should be gathered with replication of these findings in dif-
ferent areas of the world. Propagation of M. leprae restricted
to animal models of armadillo and gene knockout mice is the
basic resource for genetic studies. Inoculation of M. leprae
and M. lepromatosis to these animals seems to be useful in
comparison of the results for both species. The whole genome
sequencing and the further differentiation between M. lep-
rae and M. lepromatosis is a priority. The results are expect-
ed in the near future by virtue of the rapid development of
massive parallel sequencing techniques.
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